TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...